Skip to main content
. 2022 Aug;63(8):1145–1148. doi: 10.2967/jnumed.121.262940

FIGURE 2.

FIGURE 2.

Percentage change in 18F-FDG uptake (%ΔSULpeak) is plotted vs. 64Cu-DOTA-trastuzumab SUVmax measured on days 1 (A) and 2 (B). Horizontal and vertical dashed lines show, respectively, PERCIST threshold for positive response (−30%) and thresholds (day 1, 4.6 g/mL; day 2, 5.5 g/mL) that maximized accuracy of 64Cu-DOTA-trastuzumab uptake in separating responsive from nonresponsive tumors. NR = nonresponsive; R = responsive.